Animal Models for Neuroinflammation and Potential Treatment Methods.
cytokine
inflammation
lipopolysaccharide
myalgic encephalomyelitis/chronic fatigue syndrome
polyinosinic-polycytidylic acid
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
03
2022
accepted:
03
06
2022
entrez:
14
7
2022
pubmed:
15
7
2022
medline:
15
7
2022
Statut:
epublish
Résumé
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown etiology and without effective treatment options. The onset of ME/CFS is often associated with neuroinflammation following bacterial or viral infection. A positron emission tomography imaging study revealed that the degree of neuroinflammation was correlated with the severity of several symptoms in patients with ME/CFS. In animal studies, lipopolysaccharide- and polyinosinic-polycytidylic acid-induced models are thought to mimic the pathological features of ME/CFS and provoke neuroinflammation, characterized by increased levels of proinflammatory cytokines and activation of microglia. In this review, we described the anti-inflammatory effects of three compounds on neuroinflammatory responses utilizing animal models. The findings of the included studies suggest that anti-inflammatory substances may be used as effective therapies to ameliorate disease symptoms in patients with ME/CFS.
Identifiants
pubmed: 35832182
doi: 10.3389/fneur.2022.890217
pmc: PMC9271866
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
890217Informations de copyright
Copyright © 2022 Tamura, Yamato and Kataoka.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
FASEB J. 2005 Aug;19(10):1329-31
pubmed: 15919760
PLoS One. 2014 Mar 12;9(3):e90950
pubmed: 24621600
Intern Med. 2021 Aug 15;60(16):2577-2584
pubmed: 33896862
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:115-21
pubmed: 22192886
Pharmaceuticals (Basel). 2018 Jun 25;11(3):
pubmed: 29941796
Ther Adv Infect Dis. 2021 Apr 20;8:20499361211009385
pubmed: 33959278
Sci Rep. 2016 Oct 11;6:34990
pubmed: 27725700
J Neurosci Res. 2004 Oct 15;78(2):151-6
pubmed: 15378607
J Clin Med. 2021 Oct 29;10(21):
pubmed: 34768601
J Neuroinflammation. 2021 Sep 6;18(1):193
pubmed: 34488804
Anaerobe. 2013 Aug;22:50-6
pubmed: 23791918
J Clin Virol. 2006 Nov;37(3):139-50
pubmed: 16978917
Neuroscience. 2003;120(3):837-45
pubmed: 12895523
Sci Rep. 2016 Jan 13;6:19171
pubmed: 26757840
J Clin Virol. 2000 May;16(3):179-91
pubmed: 10738137
J Neuroinflammation. 2016 Apr 05;13(1):71
pubmed: 27048470
Brain Behav Immun. 2008 Mar;22(3):301-11
pubmed: 17951027
Immunol Today. 1991 Nov;12(11):404-10
pubmed: 1838480
Arch Gen Psychiatry. 2010 Jul;67(7):739-48
pubmed: 20603455
Crit Care. 2010;14(3):R88
pubmed: 20470406
Gut. 2022 Mar;71(3):544-552
pubmed: 35082169
Neurobiol Aging. 2008 Nov;29(11):1744-53
pubmed: 17543422
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Dec 20;103:109976
pubmed: 32470498
Int J Clin Exp Med. 2009;2(1):1-16
pubmed: 19436827
Int Neurourol J. 2016 May;20(Suppl 1):S2-7
pubmed: 27230456
Neuroimage. 2002 Nov;17(3):1256-65
pubmed: 12414265
Behav Brain Res. 2021 Jul 23;410:113366
pubmed: 34000339
J Nat Med. 2014 Jan;68(1):144-53
pubmed: 23760613
J Neurochem. 1997 Oct;69(4):1668-83
pubmed: 9326296
J Med Virol. 2020 Mar 4;:
pubmed: 32129496
Glia. 2019 Oct;67(10):1821-1841
pubmed: 31033014
Neuroreport. 2004 Dec 3;15(17):2571-4
pubmed: 15570154
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):760-8
pubmed: 20600462
J Med Virol. 2017 Sep;89(9):1636-1645
pubmed: 28303641
J Nucl Med. 2014 Jun;55(6):945-50
pubmed: 24665088
Med Sci Monit. 2011 Apr;17(4):SC11-5
pubmed: 21455120
Brain Behav Immun. 2010 Aug;24(6):996-1007
pubmed: 20399848
Front Neurol. 2018 Jan 23;9:8
pubmed: 29410649
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Microbiome. 2017 Jun 23;5(1):63
pubmed: 28645307
J Neuroinflammation. 2014 Jul 28;11:132
pubmed: 25065370
Brain Behav Immun. 2018 Oct;73:364-374
pubmed: 29852290
Int J Biol Sci. 2022 Jan 1;18(1):441-458
pubmed: 34975343
Biochem Pharmacol. 2005 Dec 5;70(12):1772-84
pubmed: 16256955
Br J Pharmacol. 2013 May;169(2):337-52
pubmed: 23441623
Glia. 2014 Sep;62(9):1407-17
pubmed: 24852223
Int J Neurosci. 2014 May;124(5):307-21
pubmed: 23930978
J Inflamm Res. 2008;1:29-39
pubmed: 22096345
Trends Mol Med. 2021 Sep;27(9):895-906
pubmed: 34175230
Adv Virol. 2012;2012:205085
pubmed: 22927850
Metab Brain Dis. 2019 Apr;34(2):385-415
pubmed: 30758706
Lancet. 2006 Jan 28;367(9507):346-55
pubmed: 16443043
J Affect Disord. 2007 Apr;99(1-3):237-40
pubmed: 17007934
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
J Intern Med. 2022 Jun;291(6):801-812
pubmed: 35212063
BMC Neurol. 2004 Oct 04;4(1):14
pubmed: 15461817
Eur J Med Chem. 2021 Apr 15;216:113250
pubmed: 33691258
Brain Behav Immun. 2007 May;21(4):490-502
pubmed: 17321719
J Neuroinflammation. 2012 Jun 18;9:130
pubmed: 22709825
J Neurosci Res. 2009 May 1;87(6):1381-8
pubmed: 19115408
J Neurol Neurosurg Psychiatry. 1993 Jun;56(6):679-83
pubmed: 8509783
Brain Behav Immun. 2015 Aug;48:274-86
pubmed: 25900439
J Med Virol. 2010 Oct;82(10):1684-8
pubmed: 20827765
Glia. 1993 Jan;7(1):75-83
pubmed: 8423065
Trends Neurosci. 1997 Dec;20(12):565-70
pubmed: 9416669